Beam Therapeutics (BEAM) Stock Price & Analysis

BEAM$22.83-1.20 -4.99%
BiotechnologyGrowth Stock
Compare
Market cap$2.36BEnterprise value$2.90BRevenue (TTM)$146.64MMarket position—

Score

68
Bullish
Value
58
Quality
45
Growth
100

AI Analysis

Snapshot

Beam Therapeutics is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 68/100) in Biotechnology. Under the hood: revenue compounding ~186% annually over recent years. Street targets still imply ~189% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

58
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

45
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Beam Therapeutics Inc. (BEAM) last printed $22.83. Equity value is $2.36B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

201720182019202020212022202320242025
$0.00$0.00$18,000.00$24,000.00$51.84M$60.92M$377.71M$63.52M$139.74M

About

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Beam Therapeutics (BEAM) Stock Price & Analysis

BEAM price $22.83 -1.20 -4.99%

Ticker
BEAM
Price
$22.83
Change
-1.20 -4.99%
Market cap
$2.36B
Dividend yield
0.00%
Beta
2.22
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
68
Value
58
Quality
45
Growth
100

Stocklytics score rationale: value 58, quality 45, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener